Skip to main content
. Author manuscript; available in PMC: 2026 Jun 19.
Published in final edited form as: Cell Rep. 2018 Dec 26;25(13):3706–3720.e8. doi: 10.1016/j.celrep.2018.12.017

Figure 4. Senescence Marker-Positive VEGFR TKI-Resistant Cells Contribute to Withdrawal-Mediated Rebound Growth.

Figure 4.

(A) 4T1P and 4T1AxR cells were incubated with C12FDG and positive cells quantified (n = 3).

(B) C12FDG-incubated 4T1AxR cells were sorted into C12FDG+ and C12FDG− cell populations for in vitro and in vivo testing.

(C and D) In vitro comparison of cell proliferation at day 4 shown by (C) cell counting (right; representative images shown in left) and (D) MTS assay (n = 4–5).

(E) Comparison of 4T1AxR C12FDG+ and 4T1AxR C12FDG− PT growth following orthotopic implantation of in BALB/c (left; n = 27), and OS following surgical resection (right; n = 14–15; surgery on day 14).

P, parental; AxR, axitinib-resistant; OS, overall survival; PT, primary tumor. Quantitative data are shown as mean ± SD or SEM for in vivo experiment; *p < 0.05 and **p < 0.01, compared to 4T1AxR C12FDG− cells, unless noted otherwise.